Literature DB >> 2427685

Depolarization-dependent binding of the calcium channel antagonist, (+)-[3H]PN200-110, to intact cultured PC12 cells.

D A Greenberg, C L Carpenter, R O Messing.   

Abstract

Voltage-dependent Ca++ channels of excitable cell membranes are coupled to drug recognition sites that influence Ca++ channel gating behavior. In cardiac tissue, these sites are themselves regulated by membrane potential, which may explain the apparent dependence of drug effects on Ca++ channel conductance state. Whether a similar relationship pertains in other (e.g., neural) cells is unknown. To examine this issue, we investigated the effect of K+-depolarization on binding of the dihydropyridine Ca++ channel antagonist, (+)-[3H]PN200-110, to intact PC12 cells in culture. Specific (nifedipine-sensitive) binding of 50 pM (+)-[3H]PN200-110 to intact PC12 cells was increased approximately 3-fold by K+-depolarization. Binding was also increased when membrane potential was abolished by treatment with digitonin; elevated [K+] had no additional effect under these conditions. Enhancement of binding by K+-depolarization was reversible upon repolarization and resulted from an increase in binding affinity (decrease in KD from 274 to 55 pM in equilibrium saturation experiments and from 625 to 44 pM in kinetic studies), without an increase in binding site number. These findings are in accord with a modulated receptor model of Ca++ channel function in which affinity for dihydropyridine Ca++ channel antagonists is enhanced by depolarization, and provide evidence that this form of Ca++ channel regulation occurs in neural, as well as muscle, cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427685

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Regulation of the L-type calcium channel alpha-1 subunit by chronic depolarization in the neuron-like PC12 and aortic smooth muscle A7r5 cell lines.

Authors:  O Feron; T Godfraind
Journal:  Pflugers Arch       Date:  1995-07       Impact factor: 3.657

2.  Differential expression by nerve growth factor of two types of Ca2+ channels in rat phaeochromocytoma cell lines.

Authors:  M M Usowicz; H Porzig; C Becker; H Reuter
Journal:  J Physiol       Date:  1990-07       Impact factor: 5.182

3.  Calcium currents in the A7r5 smooth muscle-derived cell line.

Authors:  T N Marks; G R Dubyak; S W Jones
Journal:  Pflugers Arch       Date:  1990-12       Impact factor: 3.657

4.  Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain.

Authors:  N Morel; T Godfraind
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

5.  Investigations of the roles of dihydropyridine and omega-conotoxin-sensitive calcium channels in mediating depolarisation-evoked endogenous dopamine release from striatal slices.

Authors:  H Herdon; S R Nahorski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

6.  Evidence for the presence of regional differences in the calcium antagonist receptors in lower urinary tract smooth muscle.

Authors:  J Latifpour; M Yoshida; R M Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

7.  Dihydropyridine binding and Ca(2+)-channel characterization in clonal calcitonin-secreting cells.

Authors:  D Krautwurst; H Scherübl; T Kleppisch; J Hescheler; G Schultz
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

8.  Characterization in rat aorta of the binding sites responsible for blockade of noradrenaline-evoked calcium entry by nisoldipine.

Authors:  N Morel; T Godfraind
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

9.  A calcium channel antagonist stereoselectively decreases ethanol withdrawal hyperexcitability but not that due to bicuculline, in hippocampal slices.

Authors:  M A Whittington; H J Little
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.